{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:11:40Z","timestamp":1780629100664,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejca.2018.06.030","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T19:28:03Z","timestamp":1533670083000},"page":"229-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600\u2013mutant metastatic melanoma"],"prefix":"10.1016","volume":"101","author":[{"given":"Guy","family":"Ben-Betzalel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erez N.","family":"Baruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Boursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Steinberg-Silman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nethanel","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Shapira-Frommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Schachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Markel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.06.030_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ijc.27616","article-title":"International trends in the incidence of malignant melanoma 1953-2008\u2013are recent generations at higher or lower risk?","volume":"132","author":"Erdmann","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2018.06.030_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cps.2009.07.001","article-title":"Epidemiology, staging (new system), and prognosis of cutaneous melanoma","volume":"37","author":"Cho","year":"2010","journal-title":"Clin Plast Surg"},{"key":"10.1016\/j.ejca.2018.06.030_bib3","first-page":"247","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.ejca.2018.06.030_bib4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.06.030_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","article-title":"BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site","volume":"24","author":"Bauer","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ejca.2018.06.030_bib6","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2018.06.030_bib7","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.06.030_bib8","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejca.2018.06.030_bib9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.06.030_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/s10147-018-1259-6","article-title":"Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update","author":"Nagai","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.06.030_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/CMR.0000000000000392","article-title":"A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma","volume":"27","author":"Yuki","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2018.06.030_bib12","first-page":"e1310","article-title":"Acute inflammatory demyelinating polyneuroradiculopathy with ipilimumab in metastatic melanoma: a case report and review of literature","volume":"9","author":"Rupareliya","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.ejca.2018.06.030_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2017.08.019","article-title":"Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach","volume":"47","author":"Iglesias","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejca.2018.06.030_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with Pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2018.06.030_bib15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejca.2018.06.030_bib16","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-17-0220","article-title":"Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1\/PD-l1 therapy for immune-related adverse events","author":"Martini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2018.06.030_bib17","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.06.030_bib18","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.06.030_bib19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2018.06.030_bib20","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2018.06.030_bib21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejca.2018.06.030_bib22","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.06.030_bib23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.06.030_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.06.030_bib25","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.06.030_bib26","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2018.06.030_bib27","doi-asserted-by":"crossref","first-page":"e22890","DOI":"10.4161\/onci.22890","article-title":"Vemurafenib enhances MHC induction in BRAFV600Ehomozygous melanoma cells","volume":"2","author":"Sapkota","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejca.2018.06.030_bib28","article-title":"Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib","author":"Wongchenko","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ejca.2018.06.030_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.neo.2018.01.012","article-title":"Regulation of CEACAM1 protein expression by the transcription factor ETS-1 in BRAF-mutant human metastatic melanoma cells","volume":"20","author":"Kfir-Elirachman","year":"2018","journal-title":"Neoplasia N Y N"},{"key":"10.1016\/j.ejca.2018.06.030_bib30","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.5301\/tj.5000253","article-title":"Association of vitiligo and response in patients with metastatic malignant melanoma on temozolomide","volume":"101","author":"Tatli","year":"2015","journal-title":"Tumori"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918309444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918309444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T20:21:29Z","timestamp":1571689289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918309444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":30,"alternative-id":["S0959804918309444"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.06.030","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600\u2013mutant metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}